1- (3- tert- butyl- 1- phenyl- 1H- pyrazol- 5- yl)- 3- (2- fluoro- 4- (3- oxo- 3,4- dihydropyrido(3,2- b)pyrazin- 8- yloxy)phenyl)urea

a RAF inhibitor with antineoplastic activity; structure in first source

Also Known As:

CCT196969

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido(3,2-b)pyrazin-8-yloxy)phenyl)urea: 2
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido(3,2-b)pyrazin-8-yloxy)phenyl)urea: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - 1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido(3,2-b)pyrazin-8-yloxy)phenyl)urea: 2

Experts

1.	Elmquist, William F: 1 article (01/2019)
2.	Gampa, Gautham: 1 article (01/2019)
3.	Kim, Minjee: 1 article (01/2019)
4.	Mladek, Ann C: 1 article (01/2019)
5.	Mohammad, Afroz S: 1 article (01/2019)
6.	Parrish, Karen E: 1 article (01/2019)
7.	Sarkaria, Jann N: 1 article (01/2019)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/2022 - "Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis." 01/01/2022 - "Using in vitro cell line assays, we studied the effects of CCT196969 in multiple melanoma brain metastasis cell lines. " 01/01/2022 - "CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells."
2.	Melanoma (Melanoma, Malignant) 01/01/2022 - "Furthermore, CCT196969 inhibited viability in two B-Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. " 01/01/2022 - "Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis." 01/01/2022 - "Using in vitro cell line assays, we studied the effects of CCT196969 in multiple melanoma brain metastasis cell lines. " 01/01/2022 - "CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells." 01/01/2022 - "CCT196969 is a SRC family kinase (SFK) and Raf proto-oncogene, serine/threonine kinase (RAF) inhibitor with documented effects in primary melanoma cell lines in vitro and in vivo. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2019 - "The purpose of this study was to perform a quantitative assessment and evaluation of the influence of efflux mechanisms at the blood-brain barrier (BBB), in particular, Abcb1/P-glycoprotein (P-gp) and Abcg2/breast cancer resistance protein (Bcrp), on the brain distribution of three panRAF inhibitors: CCT196969 [1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea], LY3009120 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea, and MLN2480 [4-pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-]. "

Related Drugs and Biologics

1.	Member 1 Subfamily B ATP Binding Cassette Transporter
2.	Urea (Carbamide)
3.	Proteins (Proteins, Gene)
4.	tovorafenib
5.	LY3009120
6.	src-Family Kinases
7.	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)